In addition, the number and the percentages of patients with NT-proBNP higher than 5,180 pg/ml in the CR group significantly decreased (p < 0.05), which suggested that phase 1 CR could further lower plasma NT-proBNP level and improve short-term prognosis of patients with CHD and AHF based on the routine medicine. This evidence concerns the gene NPPB and coronary artery disorder.